Clinical trials
Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials
Below are recruiting recurrent or metastatic nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 2,322 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06635980RecruitingPhase 2
Radiation before or after breast cancer surgery
This trial compares two ways of giving radiation for breast cancer that has not spread: before or after surgery. It aims to see if giving radiation first might work as well or better.
Scottsdale, ArizonaAges 18 years+ - NCT06553885RecruitingPhase 2
Study of enfortumab vedotin for advanced colorectal or liver cancer
This trial tests a drug called enfortumab vedotin for people whose colorectal or liver cancer has spread or cannot be removed and has stopped responding to or is intolerant to standard treatments. The drug is given through a vein and works by targeting cancer cells.
Tampa, FloridaAges 18 years+ - NCT06532539RecruitingPhase 2
Cadonilimab with radiation for recurrent endometrial cancer
This trial tests a combined treatment of the immunotherapy drug cadonilimab plus radiation and chemotherapy for endometrial cancer that has come back or spread to only a few places. The goal is to see if this combination can help control the cancer better.
Jinan, ShandongAges 18–80 - NCT06492759RecruitingPhase 2
High-dose radiation with pembrolizumab and chemo for pd-l1 positive tnbc
This trial tests giving high-dose radiation along with the immunotherapy drug pembrolizumab and chemo to people with a specific subtype of advanced breast cancer (PD-L1 positive triple negative). It may help shrink tumors and keep them from growing.
Atlanta, GeorgiaAges 18 years+ - NCT06484153RecruitingPhase 2
New drug combo for advanced colorectal cancer
This trial tests a new combination of three drugs—fruquintinib (a targeted therapy), pirfenidone (an anti-fibrotic drug), and an immunotherapy (anti-PD-1)—for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this triple therapy can shrink tumors more effectively than current options.
Wuhan, HubeiAges 18–75 - NCT06476067Recruiting
Predicting early esophageal cancer return after surgery
This trial uses stored tumor tissue to try to predict if esophageal cancer will come back early after surgery. It is for people who had surgery only (no chemo or radiation) and have been followed for at least 2 years.
Nagoya, Aichi-kenAges 20 years+ - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT06447103RecruitingPhase 2
New scan to find kidney cancer after surgery
This trial tests a special PET scan to see if it can better find leftover kidney cancer after surgery compared to a standard CT scan. You may qualify if you had kidney cancer surgery within the last 4-16 weeks and are at high risk of the cancer coming back.
Los Angeles, CaliforniaAges 18 years+ - NCT06320405RecruitingPhase 1/Phase 2
Combination therapy for advanced solid tumors
This trial tests a combination of three drugs—axatilimab, retifanlimab, and paclitaxel—for people with advanced solid tumors that have spread. It aims to see if this combination can shrink tumors or slow their growth, and it is for people who have already tried taxane chemotherapy.
Portland, OregonAges 18 years+ - NCT05965856RecruitingPhase 2
Testing two antibody medicines for advanced bladder and other cancers
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06254248RecruitingPhase 2
Safety of two cancer drugs after liver transplant
This trial tests a combination of two drugs (atezolizumab and bevacizumab) for people whose liver cancer has returned after a liver transplant and cannot be treated with surgery or other local procedures. The goal is to see if this treatment is safe for liver transplant recipients.
ClichyAges 18–90 - NCT05945875RecruitingPhase 1
Dual scans to find head and neck cancer spread
This early-stage study tests two different imaging (scanning) methods to better detect head and neck cancer. Your results from the scans may help doctors see where disease is before standard surgery to remove lymph nodes in the neck.
Nashville, TennesseeAges 19 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT06176261RecruitingPhase 2
Datopotamab deruxtecan for breast cancer with brain spread
This trial tests a new drug called datopotamab deruxtecan for people with HER2-negative breast cancer that has spread to the brain. It looks at how well the drug works against brain metastases.
Miami, FloridaAges 18 years+ - NCT06173349RecruitingPhase 1
New bladder therapy for BCG-resistant bladder cancer
This trial tests a new treatment for bladder cancer that does not respond to standard BCG therapy. The treatment uses tiny particles (micelles) that deliver a chemotherapy drug directly into the bladder, aiming to destroy cancer cells without needing surgery.
Sacramento, CaliforniaAges 18 years+ - NCT06157060Recruiting
Predicting liver cancer return after surgery with a blood test
This trial is for people with early-stage liver cancer who are scheduled for surgery. It uses a simple blood test to look for tiny bits of tumor DNA after treatment, which may help predict if the cancer will come back.
Foshan, GuangdongAges 18–75 - NCT06081959RecruitingPhase 3
Study of SKB264 for advanced HR+/HER2- breast cancer
This trial tests a new drug called SKB264 for people with a common type of breast cancer (HR+/HER2-) that has spread or come back and has not responded to at least one round of chemotherapy. It aims to see if this treatment can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT05997017RecruitingPhase 2
Nab-sirolimus plus letrozole for advanced endometrial cancer
This trial tests a combination of two drugs—nab-sirolimus and letrozole—for people with advanced or returning endometrioid endometrial cancer. The goal is to see if this combination can shrink tumors or slow cancer growth.
Little Rock, ArkansasAges 18 years+ - NCT06023862RecruitingPhase 2
Study of dostarlimab and bevacizumab for recurrent clear cell cancer
This trial tests a drug called dostarlimab alone or with bevacizumab compared to standard chemotherapy for women whose clear cell cancer of the ovary, uterus, cervix, vagina, or vulva has come back within a year of platinum chemotherapy. The goal is to see if these newer treatments can help control the cancer better.
Clayton, Clayton Rd.Ages 18 years+ - NCT05901545RecruitingPhase 1
Test an iodine-labeled drug to map neck lymph nodes
This Phase 1 study tests a labelling of panitumumab with iodine (111In) to see how well it can identify lymph nodes in head and neck cancer before surgery. The goal is to improve lymph node staging (which can help guide treatment), with the main focus on safety and early performance.
Nashville, TennesseeAges 19 years+ - NCT04204850RecruitingPhase 2
Cabozantinib for liver cancer that returns after liver transplant
This trial studies cabozantinib, a cancer medicine, for liver cancer that has come back after a liver transplant. It’s for people whose cancer can’t be cured with more surgery or local procedures, to see if the treatment can help control the disease.
Toronto, OntarioAges 18 years+ - NCT05595408Recruiting
Tracking tumor DNA to predict relapse after upper kidney cancer surgery
This study checks tumor DNA found in blood and urine to see who is at higher risk of the cancer coming back after surgery. It may help doctors identify “minimal residual disease,” meaning tiny amounts of cancer that can remain after treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05613413RecruitingPhase 2
Maintenance cabozantinib plus pembrolizumab after lung cancer control
This trial tests whether continuing treatment with cabozantinib plus pembrolizumab after your metastatic squamous lung cancer responds (or is stable) can help people live longer and stay in control. It may be an option if your cancer has already shown it can respond to initial (first-line) treatment.
Chicago, IllinoisAges 18 years+ - NCT05562830RecruitingPhase 1/Phase 2
Study for bladder or urinary tract cancer after PD-1 failure
This Phase 1/2 study tests investigational cancer treatment(s) in people with locally advanced or metastatic urothelial cancer that has not responded to PD-1/PD-L1 immunotherapy. It may help by trying a new approach after prior checkpoint treatment has stopped working or the cancer returns.
Orange, CaliforniaAges 18 years+
Hear when a new Recurrent or Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 2,322 recruiting recurrent or metastatic nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent Nasopharyngeal Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Squamous Cell Carcinoma
- Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Metastatic Renal Cell Carcinoma
- Nasopharyngeal Carcinoma (NPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.